Back to search
FDAFDA · Food and drugs·Recall number Z-0185-2019

CyPass System 241-S, CYPASS MICRO-STENT, CYPASS LOADED, CYPASS APPLIER, REF CATALOG #: 8065754003 For ophthalmic use.

Published October 31, 2018 · Recall initiated: August 28, 2018

Summary

FDA records medical device Class I recall Z-0185-2019, published October 31, 2018 and initiated August 28, 2018. Recalling firm: Alcon Research, LTD.; Status: Terminated; Reported quantity: 30561 units; Lot: GTIN: 00380657540037 All lot/serial numbers. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Alcon Research, LTD.
Distributor
Worldwide distribution. US nationwide including Puerto Rico, Argentina, Australia, Austria, Canada, Chile, Colombia, Costa Rica, Denmark, Dominican Republic, Ecuador, France, Finland, Germany, Hong Kong, Iceland, Italy, Mexico, Peru, Singapore, Spain, Sweden, Switzerland, United Kingdom, and Uruguay.
Lot
GTIN: 00380657540037 All lot/serial numbers
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was CyPass System 241-S, CYPASS MICRO-STENT, CYPASS LOADED, CYPASS APPLIER, REF CATALOG #: 8065754003 For ophthalmic use. recalled?

Yes. FDA published recall Z-0185-2019 on October 31, 2018. Reported hazard: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.

What should I do if I have this product?

Voluntary: Firm initiated · Letter